T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins.
T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins.
复制标题
DOI：
10.1093/abt/tbz001
复制
发表时间：
2019-01
影响因子：
--
通讯作者：
An Z
中科院分区：
文献类型：
--
作者：
Xu Y;Salazar GT;Zhang N;An Z
T细胞受体模拟(TCRm)抗体结合了T细胞靶向细胞内抗原的能力和抗体特有的其他能力。新抗原是由于体细胞突变而产生的异常蛋白质。技术进步促进了新抗原靶向治疗的发展，包括TCRm抗体治疗。本文总结了TCRm抗体的主要特征，特别是针对新抗原的抗体，并进一步介绍了推进TCRm治疗必须克服的障碍的讨论。
T-cell receptor mimic (TCRm) antibodies combine the capacity of a T cell to target intracellular antigens with other capacities unique to antibodies. Neoantigens are abnormal proteins that arise as a consequence of somatic mutations. Technological advances promote the development of neoantigen-targeting therapies including TCRm antibody therapies. This review summarizes key characteristics of TCRm antibodies, in particular those targeting neoantigens, and further introduces discussion of obstacles that must be overcome to advance TCRm therapeutics.